Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis | Taiwan News | Sep. 4, 2025 13:01

Contributing sentiments towards policy:

57% : For the EU, EU reference countries and Japan, the co-primary endpoints comprised the proportion of patients with vIGA-AD 0/1 and a reduction from baseline score of ≥2 points along with the proportion of patients reaching a 75% or greater improvement in the eczema area and severity index total score (EASI-75).
55% : In both analyses non-responder imputation for patients with prohibited medication use and missing data.
46% : It has the potential to be a first- or best-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including the anchor indication of moderate-to-severe AD, and potentially in moderate-to-severe asthma, systemic sclerosis, celiac disease, and alopecia areata.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.